減量薬の中止が食事療法終了よりも速い体重再増加と関連することを発見(New study finds that stopping weight-loss drugs is linked to faster regain than ending diet programmes)

ad

2026-01-08 オックスフォード大学

オックスフォード大学の研究チームは、GLP-1受容体作動薬などの減量薬を中止すると、食事療法のみを終えた場合よりも体重が早く再増加することを示した。複数の臨床研究データを解析した結果、薬物療法中は食欲抑制や代謝調整により体重減少が進む一方、投与終了後は生理的反動が強く、体重回復の速度が加速する傾向が確認された。研究者らは、減量薬を短期的な解決策と捉えるのではなく、長期的な体重管理戦略や生活習慣改善と組み合わせて用いる必要性を強調している。本研究は、肥満治療における薬物依存のリスクと、継続的支援の重要性を示す知見を提供する。

<関連情報>

体重管理薬中止後の体重増加:系統的レビューとメタアナリシス Weight regain after cessation of medication for weight management: systematic review and meta-analysis

Sam West, postdoctoral researcher;Jadine Scragg, postdoctoral researcher;Paul Aveyard, professor;Jason L Oke, departmental lecturer;Lia Willis, research assistant;Stella J P Haffner, research assistant;Heather Knight, research assistant;Danni Wang, research fellow;Sarah Morrow, clinical doctoral fellow;Laura Heath, clinical doctoral fellow;Susan A Jebb, professor;Dimitrios A Koutoukidis, associate professor
The BMJ  Published 07 January 2026
DOI:https://doi.org/10.1136/bmj-2025-085304

減量薬の中止が食事療法終了よりも速い体重再増加と関連することを発見(New study finds that stopping weight-loss drugs is linked to faster regain than ending diet programmes)

Abstract

Objectives To quantify and compare the rate of weight regain after cessation of weight management medications (WMMs) in adults with overweight or obesity.

Design Systematic review and meta-analysis.

Study selection Trial registries and databases (Medline, Embase, PsycINFO, CINAHL, Cochrane, Web of Science, and trial registries) were searched from inception until February 2025 for randomised controlled trials (RCTs), non-randomised trials, and observational studies that included WMM (≥8 weeks) with follow-up for ≥4 weeks after cessation of treatment in adults with overweight or obesity. Comparators were any non-drug weight loss intervention or placebo.

Data extraction and synthesis The review followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Two independent reviewers screened titles, extracted data, and assessed the risk of bias using the Cochrane Risk of Bias 2 tool for RCTs and the ROBINS-I tool for non-randomised trials. Data were analysed using mixed effect, meta-regression, and time-to-event models. Weight regain after cessation of WMM was compared with that reported after cessation of behavioural weight management programmes (BWMPs).

Main outcome measures The primary outcome was rate of weight regain from end of treatment, with associated changes in cardiometabolic markers as a secondary outcome.

Results Of the 9288 titles screened, 37 studies (63 intervention arms, 9341 participants) were included. Average treatment duration was 39 (range 11-176) weeks, with average follow-up of 32 (4-104) weeks. The average monthly rate of weight regain was 0.4 kg (95% confidence interval (CI) 0.3 to 0.5) (mixed model 0.3 kg (0.2 to 0.4) monthly v control in RCTs). All cardiometabolic markers were projected to return to baseline within 1.4 years after the cessation of WMM. Weight regain was faster after WMM than after BWMP (by 0.3 kg (0.22 to 0.34) monthly), independent of initial weight loss. Estimates and precision were robust in sensitivity analyses.

Conclusions This review found that cessation of WMM is followed by rapid weight regain and reversal of beneficial effects on cardiometabolic markers. Regain after WMM was faster than after BWMP. These findings suggest caution in short term use of these drugs without a more comprehensive approach to weight management.

Systematic review registration PROSPERO CRD42024532069.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました